LabCorp Feels the Squeeze

LabCorp has felt the market's sting in the third quarter, posting a decline in profits — its fourth consecutive reduction — and hedged its bets by lowering the low end and raising the high end of its previous 2011 revenue projection.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Kirell, can you estimate what

Kirell, can you estimate what LabCorp's growth rate would have been without the acquisitions? I would expect that the acquired Genzyme Genetics tests would contribute significantly to the higher revenue per requisition, which was the main factor in LabCorp's revenue growth.